Metastatic breast cancer on pembrolizumab/eribulin
65 fecal/saliva samples (cross-sectional) from metastatic breast cancer patients receiving pembrolizumab plus eribulin, studying gut and oral microbiota composition during treatment. machine-written summary
65 samples · 65 runs · Age unknown · 2024 · 9.06 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 195 sample values (intervention, intervention detail, timepoint) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 195 sample values (health condition, health condition detail, sex) · PMC11977384 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet · share metadata |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention · arms resolved
design single_arm_before_after
longitudinal — not resolved
Schedule stated by the source: “Baseline, after three treatment cycles (Cycle 4 Day 1), and end-of-treatment (EoT)” (time origin: intervention start).
Genera, mean relative abundance over 54 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 0 | 0% | ||||
| country | 0 | 0% | ||||
| health_condition | 65 | 100% | 65 | |||
| subject_id | 0 | 0% | ||||
| health_condition_detail | 65 | 100% | 65 | |||
| intervention | 65 | 100% | 65 | |||
| intervention_detail | 65 | 100% | 65 | |||
| sex | 65 | 100% | 65 | |||
| timepoint_label | 65 | 100% | 65 |
- Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin. 2025 PMID 40207279 PMC11977384 own_data
- Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin 2024 own_data
Archive description
Human gut metagenome sequences of metastatic breast cancer patients receiving pembrolizumab and eribulin
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.80. Assay shotgun_dna.
- host run.host_tax_id · “9606”
- body site study.description · “Human gut metagenome sequences”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN38783766 | health_condition | other_cancer | R3 | 0.70 | paper.fulltext.abstract | metastatic breast cancer (mBC) who had received prior treatments |
| SAMN38783766 | health_condition_detail | HR-positive/HER2-negative metastatic breast cancer patients treated with pembrolizumab and eribulin | R3 | 0.70 | paper.fulltext.abstract | metastatic breast cancer (mBC) who had received prior treatments |
| SAMN38783766 | intervention | no_intervention | R1 | 0.90 | biosample.attribute:Timepoint | Timepoint: Baseline |
| SAMN38783766 | intervention_detail | baseline before drug therapy | R1 | 0.90 | biosample.attribute:Timepoint | Timepoint: Baseline |
| SAMN38783766 | sex | female | R3 | 0.60 | paper.fulltext.results | Female (%): age, median (IQR), years 100 |
| SAMN38783766 | timepoint_label | Baseline | R1 | 0.85 | sample.attr.timepoint | Baseline |
Sequencing
65 runs over 65 samples · mean 8.28 Gbp per run (median 9.06 Gbp, total 538.06 Gbp; 65 runs with a base count) · layout PAIRED 65 · platform ILLUMINA 65 · models Illumina NovaSeq 6000 (65) · 83% of runs with a Sandpiper profile · first public 2024-12-29
Authors (28)
Teng NM first · Malfettone A · Dalby MJ · Kiu R · Seki D · Robinson T · Gion M · Bermejo B · Pérez-García JM · Prat A · Vázquez RM · Llombart-Cussac A · Curigliano G · Schmid P · Barroso-Sousa R · Mancino M · Shimizu E · Rodríguez-Morató J · Mina L · Hall LJ · Robinson SD · Cortés J last · Robinson S first · Teng n · Dalby M · Pérez-García J · Vázquez R · Hall L
Help complete this project
3 of the 4 core fields are below 50% coverage: age_category, country, subject_id. Share metadata
Downloads
PRJNA1050903.csv.gz (2.6 KB) · parquet (72.9 KB) — all 65 samples, every field with route and confidence · PRJNA1050903_determinations.csv.gz (2.9 KB) — 390 evidence rows